Simulations Plus (SLP) 6.04 $SLP
Simulations Plus Announces Quarterly Cash Dividend
Business Wire - Wed Apr 30, 7:02AM CDT
Simulations Plus, Inc. (NASDAQ: SLP), a leading provider of simulation and modeling software for pharmaceutical discovery and development, today announced that its Board of Directors has decided to distribute a $0.05 per share cash dividend in May 2014.
Merck, P&G and Other Dividend Stocks You Wish You'd Bought in 2013
at The Street - Thu Apr 24, 5:00AM CDT
I've covered these dividend winners before, but you're not too late to get on board.
Three Dividend Stocks in Bullish Trends
at The Street - Fri Apr 11, 10:36AM CDT
These stocks offer generous dividend yields and the opportunity for appreciation.
Simulations Plus Up 34.6% Since SmarTrend Uptrend Call (SLP)
Comtex SmarTrend(R) - Thu Apr 10, 9:12AM CDT
SmarTrend identified an Uptrend for Simulations Plus (NASDAQ:SLP) on June 4th, 2013 at $4.57. In approximately 10 months, Simulations Plus has returned 34.61% as of today's recent price of $6.15.
Simulations Plus Reports Second Quarter FY2014 Financial Results
Business Wire - Wed Apr 09, 7:02AM CDT
Simulations Plus, Inc. (NASDAQ: SLP), a leading provider of simulation and modeling software for pharmaceutical discovery and development, today reported financial results for its second quarter of fiscal year 2014 ended February 28, 2014 (2QFY14) and first six months of fiscal year 2014 (6moFY14).
Simulations Plus Sets Date for 2nd Quarter 2014 Earnings Release and Conference Call
Business Wire - Fri Apr 04, 1:00PM CDT
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of software and consulting services for pharmaceutical R&D and environmental toxicology, announced that it expects to file its quarterly report on Form 10-Q for the second quarter of its 2014 fiscal year, ended February 28, 2014, with the U.S. Securities and Exchange Commission on Wednesday, April 9, 2014. Chairman and Chief Executive Officer Walt Woltosz will host a conference call to discuss the Company's performance on Wednesday, April 9, at 1:15 p.m. PT/4:15 p.m. ET.
Simulations Plus Predictor improves all predictions, adds new ones
M2 - Thu Mar 27, 7:43AM CDT
Simulations Plus, Inc. (NASDAQ: SLP) said it has released version 7.0 of its best-in-class ADMET Predictor molecular property prediction software.
Simulations Plus Shares Up 46.7% Since SmarTrend's Buy Recommendation (SLP)
Comtex SmarTrend(R) - Wed Mar 26, 11:01AM CDT
SmarTrend identified an Uptrend for Simulations Plus (NASDAQ:SLP) on June 4th, 2013 at $4.57. In approximately 10 months, Simulations Plus has returned 46.70% as of today's recent price of $6.70.
Simulations Plus Releases ADMET Predictor Version 7.0
Business Wire - Wed Mar 26, 7:02AM CDT
Simulations Plus, Inc. (NASDAQ:SLP), a leading provider of consulting services and software for pharmaceutical discovery and development, today announced that it has released version 7.0 of its best-in-class ADMET Predictor(TM) molecular property prediction software.
Simulations Plus Has Returned 36.3% Since SmarTrend Recommendation (SLP)
Comtex SmarTrend(R) - Wed Mar 19, 9:47AM CDT
SmarTrend identified an Uptrend for Simulations Plus (NASDAQ:SLP) on June 4th, 2013 at $4.57. In approximately 10 months, Simulations Plus has returned 36.30% as of today's recent price of $6.22.
Simulations Plus Signs New Partnership Agreement in China
Business Wire - Tue Mar 18, 7:01AM CDT
Simulations Plus, Inc. (NASDAQ: SLP), a leading provider of consulting services and software for pharmaceutical discovery and development, today announced that it has signed a distributor agreement with the Research Institute for Liver Diseases (RILD) in Shanghai, People's Republic of China.
Simulations Plus Announces Success in COX-2/COX-1 Drug Design Project
Business Wire - Fri Mar 14, 7:00AM CDT
Simulations Plus, Inc. (NASDAQ: SLP), a leading provider of consulting services and software for pharmaceutical discovery and development, today announced that its second NCE (new chemical entity) initiative, which involved using Simulations Plus software to design molecules to inhibit COX-2, has been a success as determined by synthesis and testing by a third-party lab. Three of the four molecules it has designed are potent inhibitors of both cyclooxygenase-2 (COX-2) and COX-1 enzymes. The fourth inhibits COX-2 but only weakly inhibits COX-1.
Simulations Plus Reports Preliminary Revenues for Second Fiscal Quarter FY2014
Business Wire - Wed Mar 05, 7:01AM CST
Simulations Plus, Inc. (NASDAQ: SLP), a leading provider of consulting services and software for pharmaceutical discovery and development, today released preliminary revenues for its second fiscal quarter of fiscal year 2014, ended February 28, 2014 (2QFY14).
Simulations Plus Shares Up 25.5% Since SmarTrend's Buy Recommendation (SLP)
Comtex SmarTrend(R) - Tue Mar 04, 5:11PM CST
SmarTrend identified an Uptrend for Simulations Plus (NASDAQ:SLP) on June 4th, 2013 at $4.57. In approximately 9 months, Simulations Plus has returned 25.52% as of today's recent price of $5.73.
Simulations Plus to work with FDA on mechanistic IVIVC modeling
M2 - Tue Mar 04, 9:23AM CST
Simulations Plus, Inc. (NASDAQ: SLP) said it has signed a five-year research collaboration agreement with the US Food and Drug Administration to work together to determine the value of mechanistic absorption modeling in developing predictive and robust in vitro-in vivo correlations.
Simulations Plus Signs Research Collaboration Agreement with FDA
Business Wire - Mon Mar 03, 7:00AM CST
Simulations Plus, Inc. (NASDAQ: SLP), a leading provider of software for pharmaceutical discovery and development, announced that it has signed a five-year research collaboration agreement (RCA) with the U.S. Food and Drug Administration (FDA) to work together to determine the value of mechanistic absorption modeling ("MAM"
in developing predictive and robust in vitro-in vivo correlations (IVIVCs). The collaboration will examine how the use of MAM can provide additional insight and greater accuracy with regards to prediction of complex drug absorption characteristics. The ultimate goal is to facilitate drug and generic product development by decreasing the regulatory burden through adequate modeling approaches.
32.5% Return Seen to Date on SmarTrend Simulations Plus Call (SLP)
Comtex SmarTrend(R) - Tue Feb 25, 11:04AM CST
SmarTrend identified an Uptrend for Simulations Plus (NASDAQ:SLP) on June 4th, 2013 at $4.57. In approximately 9 months, Simulations Plus has returned 32.53% as of today's recent price of $6.05.
Simulations Plus Announces Quarterly Cash Dividend
Business Wire - Wed Apr 30, 7:02AM CDT
Simulations Plus, Inc. (NASDAQ: SLP), a leading provider of simulation and modeling software for pharmaceutical discovery and development, today announced that its Board of Directors has decided to distribute a $0.05 per share cash dividend in May 2014.
Merck, P&G and Other Dividend Stocks You Wish You'd Bought in 2013
at The Street - Thu Apr 24, 5:00AM CDT
I've covered these dividend winners before, but you're not too late to get on board.
Three Dividend Stocks in Bullish Trends
at The Street - Fri Apr 11, 10:36AM CDT
These stocks offer generous dividend yields and the opportunity for appreciation.
Simulations Plus Up 34.6% Since SmarTrend Uptrend Call (SLP)
Comtex SmarTrend(R) - Thu Apr 10, 9:12AM CDT
SmarTrend identified an Uptrend for Simulations Plus (NASDAQ:SLP) on June 4th, 2013 at $4.57. In approximately 10 months, Simulations Plus has returned 34.61% as of today's recent price of $6.15.
Simulations Plus Reports Second Quarter FY2014 Financial Results
Business Wire - Wed Apr 09, 7:02AM CDT
Simulations Plus, Inc. (NASDAQ: SLP), a leading provider of simulation and modeling software for pharmaceutical discovery and development, today reported financial results for its second quarter of fiscal year 2014 ended February 28, 2014 (2QFY14) and first six months of fiscal year 2014 (6moFY14).
Simulations Plus Sets Date for 2nd Quarter 2014 Earnings Release and Conference Call
Business Wire - Fri Apr 04, 1:00PM CDT
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of software and consulting services for pharmaceutical R&D and environmental toxicology, announced that it expects to file its quarterly report on Form 10-Q for the second quarter of its 2014 fiscal year, ended February 28, 2014, with the U.S. Securities and Exchange Commission on Wednesday, April 9, 2014. Chairman and Chief Executive Officer Walt Woltosz will host a conference call to discuss the Company's performance on Wednesday, April 9, at 1:15 p.m. PT/4:15 p.m. ET.
Simulations Plus Predictor improves all predictions, adds new ones
M2 - Thu Mar 27, 7:43AM CDT
Simulations Plus, Inc. (NASDAQ: SLP) said it has released version 7.0 of its best-in-class ADMET Predictor molecular property prediction software.
Simulations Plus Shares Up 46.7% Since SmarTrend's Buy Recommendation (SLP)
Comtex SmarTrend(R) - Wed Mar 26, 11:01AM CDT
SmarTrend identified an Uptrend for Simulations Plus (NASDAQ:SLP) on June 4th, 2013 at $4.57. In approximately 10 months, Simulations Plus has returned 46.70% as of today's recent price of $6.70.
Simulations Plus Releases ADMET Predictor Version 7.0
Business Wire - Wed Mar 26, 7:02AM CDT
Simulations Plus, Inc. (NASDAQ:SLP), a leading provider of consulting services and software for pharmaceutical discovery and development, today announced that it has released version 7.0 of its best-in-class ADMET Predictor(TM) molecular property prediction software.
Simulations Plus Has Returned 36.3% Since SmarTrend Recommendation (SLP)
Comtex SmarTrend(R) - Wed Mar 19, 9:47AM CDT
SmarTrend identified an Uptrend for Simulations Plus (NASDAQ:SLP) on June 4th, 2013 at $4.57. In approximately 10 months, Simulations Plus has returned 36.30% as of today's recent price of $6.22.
Simulations Plus Signs New Partnership Agreement in China
Business Wire - Tue Mar 18, 7:01AM CDT
Simulations Plus, Inc. (NASDAQ: SLP), a leading provider of consulting services and software for pharmaceutical discovery and development, today announced that it has signed a distributor agreement with the Research Institute for Liver Diseases (RILD) in Shanghai, People's Republic of China.
Simulations Plus Announces Success in COX-2/COX-1 Drug Design Project
Business Wire - Fri Mar 14, 7:00AM CDT
Simulations Plus, Inc. (NASDAQ: SLP), a leading provider of consulting services and software for pharmaceutical discovery and development, today announced that its second NCE (new chemical entity) initiative, which involved using Simulations Plus software to design molecules to inhibit COX-2, has been a success as determined by synthesis and testing by a third-party lab. Three of the four molecules it has designed are potent inhibitors of both cyclooxygenase-2 (COX-2) and COX-1 enzymes. The fourth inhibits COX-2 but only weakly inhibits COX-1.
Simulations Plus Reports Preliminary Revenues for Second Fiscal Quarter FY2014
Business Wire - Wed Mar 05, 7:01AM CST
Simulations Plus, Inc. (NASDAQ: SLP), a leading provider of consulting services and software for pharmaceutical discovery and development, today released preliminary revenues for its second fiscal quarter of fiscal year 2014, ended February 28, 2014 (2QFY14).
Simulations Plus Shares Up 25.5% Since SmarTrend's Buy Recommendation (SLP)
Comtex SmarTrend(R) - Tue Mar 04, 5:11PM CST
SmarTrend identified an Uptrend for Simulations Plus (NASDAQ:SLP) on June 4th, 2013 at $4.57. In approximately 9 months, Simulations Plus has returned 25.52% as of today's recent price of $5.73.
Simulations Plus to work with FDA on mechanistic IVIVC modeling
M2 - Tue Mar 04, 9:23AM CST
Simulations Plus, Inc. (NASDAQ: SLP) said it has signed a five-year research collaboration agreement with the US Food and Drug Administration to work together to determine the value of mechanistic absorption modeling in developing predictive and robust in vitro-in vivo correlations.
Simulations Plus Signs Research Collaboration Agreement with FDA
Business Wire - Mon Mar 03, 7:00AM CST
Simulations Plus, Inc. (NASDAQ: SLP), a leading provider of software for pharmaceutical discovery and development, announced that it has signed a five-year research collaboration agreement (RCA) with the U.S. Food and Drug Administration (FDA) to work together to determine the value of mechanistic absorption modeling ("MAM"
in developing predictive and robust in vitro-in vivo correlations (IVIVCs). The collaboration will examine how the use of MAM can provide additional insight and greater accuracy with regards to prediction of complex drug absorption characteristics. The ultimate goal is to facilitate drug and generic product development by decreasing the regulatory burden through adequate modeling approaches. 32.5% Return Seen to Date on SmarTrend Simulations Plus Call (SLP)
Comtex SmarTrend(R) - Tue Feb 25, 11:04AM CST
SmarTrend identified an Uptrend for Simulations Plus (NASDAQ:SLP) on June 4th, 2013 at $4.57. In approximately 9 months, Simulations Plus has returned 32.53% as of today's recent price of $6.05.
